A Smart Tool for Health Professionals to Help New Mums with Depression

Introduction

Becoming a new mother is a profound change in life, but it can also bring unexpected challenges. One common and serious challenge is postnatal depression. For healthcare workers supporting new mothers, identifying who needs help and connecting them to the right care can be difficult. This article explores a new digital tool called PIRIMID, designed to help nurses provide smarter, more personalised support to mothers experiencing depression after childbirth.

1. The Challenge: Understanding Postnatal Depression

1.1. What is Postnatal Depression?

Postnatal depression (PND) is a form of depression that a mother can experience in the first year after giving birth. It’s more than just the “baby blues”; it’s a persistent feeling of sadness, anxiety, and exhaustion that can make it difficult to care for herself or her new baby. This is a common experience, affecting a significant number of new mothers.

To understand the scope of the problem, consider these key statistics:

• 10% to 17% of mothers will experience depression in the first year after birth.
• Approximately 15% of mothers will experience anxiety during the same period.

1.2. Why is it a Serious Issue?

The effects of untreated postnatal depression ripple outward, impacting the mother, her family, and society as a whole.

• Impact on the Mother: PND directly affects a woman’s physical, emotional, and mental wellbeing. It can diminish her ability to enjoy motherhood and cope with the daily demands of a new baby.
• Impact on the Family: The condition can strain a mother’s relationship with her partner. Crucially, it can also interfere with the mother-infant interaction, a bond that is vital for a child’s healthy emotional and cognitive development.
• Impact on Society: The societal cost is enormous. In Australia, it is estimated that perinatal mental health problems (those occurring during pregnancy or the first year after birth) create an economic burden of over $7 billion for every one-year cohort of births, largely due to the lifetime impacts on the children.

Because postnatal depression is such a serious issue, health systems have worked hard to find better ways to identify and help mothers who are struggling.

2. The Search for a Better Way to Help

2.1. The Screening Problem

One of the most common strategies to identify PND is “universal screening,” where every new mother is asked a set of standard questions to check for symptoms of depression. While this has helped increase referrals, a major gap remains between identifying a problem and getting effective help.

The core of the problem is highlighted by these two statistics:

Only 55% of women who screen positive for perinatal depression actually access treatment.

Even fewer (around 6-10%) receive an adequate dose of treatment.

This shows that simply flagging a potential problem isn’t enough.

2.2. The Need for Smarter Tools

Primary care services, where most new mothers are seen, often face challenges. They may lack integrated systems, and time-constrained health professionals need better on-the-spot guidance to make the best decisions for each mother.

This is where a Clinical Decision Support System (CDSS) comes in. A CDSS is a digital tool that supports healthcare workers in making informed, evidence-based decisions. Rather than replacing clinical judgment, it guides the professional through a structured process that brings together patient information, clinical guidelines, and expert knowledge. In the case of PIRIMID, the system helps maternal and child health nurses work through a series of steps to develop an individualised management plan tailored to each woman’s specific needs.

PIRIMID was developed as a new, innovative CDSS designed specifically to address the challenges of supporting mothers with postnatal depression.

3. Introducing PIRIMID: A New Kind of Helper

3.1. What is PIRIMID?

PIRIMID stands for Perinatal Identification, Referral, and Integrated Management for Improving Depression. It is an electronic CDSS developed to assist maternal and child health nurses (MCHNs), who are often the primary healthcare providers for new mothers.

The most innovative feature of PIRIMID is how it goes beyond a simple screening score. Many tools might just use a high score to suggest a referral. PIRIMID, however, guides the nurse to create a personalised management plan that is tailored to each woman’s specific needs, personal context, and unique situation.

3.2. How Does It Work? A Four-Step Process

The PIRIMID system guides the nurse through a structured, four-step process during the consultation with the mother.

1. Identify Key Information: The nurse reviews the mother’s screening scores, which are automatically flagged by the system if they are above a certain threshold, along with other relevant data.
2. Summarise Concerns: In consultation with the women, the nurse writes a brief, concise summary of the mother’s current situation, presenting concerns, and relevant history.
3. Develop a Formulation: The nurse combines the screening results with the mother’s personal context (like her support system or recent life events) to form a complete clinical picture.
4. Create a Management Plan: The system presents appropriate referral and follow-up options, and the nurse works with the mother to develop a collaborative plan of action.

Now that we know what PIRIMID is and how it’s designed to work, let’s look at how researchers tested whether it was effective in a real-world setting.

4. Putting PIRIMID to the Test: A Real-World Experiment

4.1. The Big Question

The researchers’ primary question was simple but crucial: Was the PIRIMID system a feasible and acceptable tool for both the nurses who would use it and the postnatal women it was designed to help? In other words, did it work in practice, and did people feel comfortable using it?

To answer this, they conducted two studies.

4.2. Study 1: The Randomised Controlled Trial

The main study was a Randomised Controlled Trial (RCT). You can think of an RCT like a classic science fair experiment where you have two groups to see which method works better. It’s a gold-standard method in medical research for comparing a new approach to the standard one.

The study recruited 229 mothers who were seen by one of 12 participating nurses. These nurses were split into two groups:

• PIRIMID Group: 6 nurses used the new PIRIMID system to guide their consultations with mothers. Halfway through the study, these nurses switched over to provide their usual care.
• Routine Care Group: 6 nurses continued with their usual method, which involved standard paper-and-pencil screening without the help of the smart system.

4.3. Study 2: The Statewide Survey

In addition to the hands-on trial, the researchers sent out a survey to maternal and child health nurses across the entire state of Victoria, Australia. A total of 292 nurses responded, providing valuable insights into their general perceptions of a tool like PIRIMID, its potential benefits, and any barriers they foresaw.

With these two studies running, the researchers were ready to see what the data would reveal about PIRIMID’s potential.

5. What Did the Researchers Discover?

5.1. Key Findings from the Trial

The results from the randomised controlled trial showed that PIRIMID was a promising tool. The key outcomes are summarised in the table below.

5.2. Insights from the Statewide Survey

The survey of 292 nurses from across the state provided a broader perspective on how a system like PIRIMID might be received. The findings were overwhelmingly positive but also highlighted practical challenges.

• Willingness to Use: An overwhelming majority (84%) of nurses said they would use a system like PIRIMID if it were available to them.
• Perceived Benefits: Nurses believed the tool would help them follow best practices, provide clear guidance for creating care plans, and improve their overall efficiency.
• Potential Barriers: The two main concerns nurses raised were time constraints during their appointments and potential technical issues like poor internet access in some locations.

These results provided a clear picture of both the promise of PIRIMID and the practical hurdles that would need to be addressed for it to succeed on a larger scale.

6. The “So What?” – Why This Research Matters

6.1. A Promising Start

This initial research, known as a “pilot study,” showed that PIRIMID is a feasible and acceptable tool. Nurses found it helpful, mothers were comfortable with it, and it seemed to help standardise the care process to be more consistent with official clinical guidelines. It represents a promising step forward in using technology to bridge the gap between screening for postnatal depression and providing effective, personalised care.

6.2. What Happens Next?

Because this was a small-scale pilot study, the results are promising but not yet conclusive. A larger, “fully powered” study is needed to determine with more certainty if PIRIMID truly improves treatment uptake and mothers’ mental health outcomes.

Crucially, the valuable feedback from this pilot is already being used to improve the system in a fully powered randomised controlled trial. This shows how research evolves based on real-world experience. Key improvements include:

• The emotional health assessment has been moved from the 4-week visit to the 8-week visit.
• Participating health services have allocated an additional 15 minutes to these visits to directly address the time constraints nurses identified.
• A digital training package was developed to make training more convenient and accessible for busy nurses.
• An option was added for mothers to complete screening on their own mobile device before their appointment, saving time during the visit.
• The next trial includes a health economic evaluation to assess if the system is not only effective but also cost-effective.

A detailed account of the research methodology and findings can be found in the full paper published in Healthcare (MDPI): https://www.mdpi.com/2227-9032/13/20/2578

 

Holt, C.; Maher, S.; Gemmill, A.W.; Booker, L.A.; Braat, S.; Koye, D.N.; Pani, B.; Buist, A.; Milgrom, J. Perinatal Identification, Referral, and Integrated Management for Improving Depression: Development, Feasibility and Pilot Randomised Controlled Trial of the PIRIMID System. Healthcare 2025, 13, 2578. https://doi.org/10.3390/healthcare13202578